Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma

NCT00615927 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00615927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00615927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent / Progressive Grade II Low-Grade Glioma
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2006
Completion date
June 30, 2012
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, gliosarcoma